promo_leaderboard Ad
‹ All stocks
BLTE

Belite Bio, Inc

BLTE · NASDAQ · Healthcare
$162.22
▼ $0.34 (-1.21%)
$142.78 $151.84 $160.90 $169.96 $162.22 Oct 18 Nov 02 Nov 17
Day range
$161.40 – $163.70
Year range
$105.88 – $200.00
Open
$163.00
Previous close
$162.56
Market cap
$6.53B
Volume (24h)
$6.0K
Volume (52w)
$970.08K
Performance
7D
▲ 2.61%
1M
▲ 9.00%
3M
▼ -4.72%
6M
▲ 11.33%
1Y
▲ 37.37%
YTD
▲ 0.84%
3Y
▲ 320.20%
5Y
▲ 1416.53%
All-time
▲ 1416.53%
Key statistics
P/E ratio
-80.31
EPS (TTM)
$-2.02
Dividend yield
—
Dividend (TTM)
—
Payout ratio
—
Shares outstanding
40.3M
About Belite Bio, Inc

Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.

Visit website
Country: United States of America
More in Healthcare